Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

BACKGROUND: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. PATIENTS AND METHODS. The medical documentation of 19 adult patients with recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesti, Tanja, Moltara, Maja Ebert, Boc, Marko, Rebersek, Martina, Ocvirk, Janja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362611/
https://www.ncbi.nlm.nih.gov/pubmed/25810706
http://dx.doi.org/10.2478/raon-2014-0021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362611/
https://www.ncbi.nlm.nih.gov/pubmed/25810706
http://dx.doi.org/10.2478/raon-2014-0021

Ejemplares similares